Nature Communications (Jul 2022)
Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
- James Brett Case,
- Samantha Mackin,
- John M. Errico,
- Zhenlu Chong,
- Emily A. Madden,
- Bradley Whitener,
- Barbara Guarino,
- Michael A. Schmid,
- Kim Rosenthal,
- Kuishu Ren,
- Ha V. Dang,
- Gyorgy Snell,
- Ana Jung,
- Lindsay Droit,
- Scott A. Handley,
- Peter J. Halfmann,
- Yoshihiro Kawaoka,
- James E. Crowe,
- Daved H. Fremont,
- Herbert W. Virgin,
- Yueh-Ming Loo,
- Mark T. Esser,
- Lisa A. Purcell,
- Davide Corti,
- Michael S. Diamond
Affiliations
- James Brett Case
- Department of Medicine, Washington University School of Medicine
- Samantha Mackin
- Department of Medicine, Washington University School of Medicine
- John M. Errico
- Department of Pathology & Immunology, Washington University School of Medicine
- Zhenlu Chong
- Department of Medicine, Washington University School of Medicine
- Emily A. Madden
- Department of Medicine, Washington University School of Medicine
- Bradley Whitener
- Department of Medicine, Washington University School of Medicine
- Barbara Guarino
- Humabs BioMed SA, a subsidiary of Vir Biotechnology
- Michael A. Schmid
- Humabs BioMed SA, a subsidiary of Vir Biotechnology
- Kim Rosenthal
- Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Kuishu Ren
- Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Ha V. Dang
- Vir Biotechnology
- Gyorgy Snell
- Vir Biotechnology
- Ana Jung
- Department of Pathology & Immunology, Washington University School of Medicine
- Lindsay Droit
- Department of Pathology & Immunology, Washington University School of Medicine
- Scott A. Handley
- Department of Pathology & Immunology, Washington University School of Medicine
- Peter J. Halfmann
- Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison
- Yoshihiro Kawaoka
- Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison
- James E. Crowe
- Vanderbilt Vaccine Center, Vanderbilt University Medical Center
- Daved H. Fremont
- Department of Pathology & Immunology, Washington University School of Medicine
- Herbert W. Virgin
- Department of Pathology & Immunology, Washington University School of Medicine
- Yueh-Ming Loo
- Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Mark T. Esser
- Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca
- Lisa A. Purcell
- Vir Biotechnology
- Davide Corti
- Humabs BioMed SA, a subsidiary of Vir Biotechnology
- Michael S. Diamond
- Department of Medicine, Washington University School of Medicine
- DOI
- https://doi.org/10.1038/s41467-022-31615-7
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 11
Abstract
SARS-CoV-2 variants of concern are less susceptible to therapeutic neutralizing antibodies, given mutations in the surface glycoprotein S. Here, Case et al. show that therapeutic antibodies S309 and AZD7442 reduce lung infection with SARSCoV-2 Omicron lineages in humanized mouse model despite the loss of neutralizing potency in vitro.
